Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data pointing to possible development of a winning medicine, there's reason to believe that more revenue could be on the way.
But as smart investors know, it matters when precisely that revenue will arrive, and how much it'll actually be in comparison to expectations. So let's unpack the importance of this program, and realistically evaluate its ability to win in the massive market for pain relief.
Vertex is known for its collection of therapies for cystic fibrosis (CF), a rare inherited disease of the lungs. But its ambitions are larger than CF alone; in collaboration with CRISPR Therapeutics, it also recently commercialized a gene therapy called Casgevy to treat or cure both sickle cell disease (SCD) and beta thalassemia. Diversifying beyond CF is a necessity in the long term, as there are only around 92,000 known CF patients in the Western world, the majority of whom the company is already treating.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 47 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 423 € is below the current price of 424.95 € for Vertex Pharmaceuticals Inc., so the potential is actually -0.46%.
